Evidence map›Paper›PMID 14982862›Full record

ArticleThe American journal of pathology2004

The plasminogen activation system reduces fibrosis in the lung by a hepatocyte growth factor-dependent mechanism.

Noboru Hattori, Shinya Mizuno, Yuka Yoshida, Kazuo Chin, Michiaki Mishima, Thomas H Sisson, Richard H Simon, Toshikazu Nakamura, Masayuki Miyake

Open access · greenAbstract read
In one paragraph

Article in The American journal of pathology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.

  1. Pooled it
  2. Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis.American journal of physiology. Lung cellular and molecular physiology · 2015
    Trial
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Pathogenesis of Systemic Sclerosis.Frontiers in immunology · 2015
    Review
  17. Always cleave up your mess: targeting collagen degradation to treat tissue fibrosis.American journal of physiology. Lung cellular and molecular physiology · 2013
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Noboru HattoriTazuke Kofukai Medical Research Institute, Department V of Oncology, Kitano Hospital, Osaka, Japan. nhattori@kitano-hp.or.jp
Shinya Mizuno
Yuka Yoshida
Kazuo Chin
Michiaki Mishima
Thomas H Sisson
Richard H Simon
Toshikazu Nakamura
Masayuki Miyake
Kitano Hospital · JPMichigan Medicine · USOsaka University · JPKyoto University · JPKyoto University Hospital · JP

Funding

SCOR IN THE PATHOBIOLOGY OF FIBROTIC LUNG DISEASEP50HL056402 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HOGABOAM, CORY M. · 1997 to 2006
$13.3M
PLASMIN, FIBRIN, AND METALLOPROTEINASES IN LUNG FIBROSISK08HL004434 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SISSON, THOMAS H · 2000 to 2004
$667k
NHLBI NIH HHS K08 HL004434NHLBI NIH HHS K08-HL-04434NHLBI NIH HHS P50 HL056402NHLBI NIH HHS P50-HL-56402
6 · The paper itself

Abstract

Mice deficient in the plasminogen activator inhibitor-1 gene (PAI-1-/- mice) are relatively protected from developing pulmonary fibrosis from bleomycin administration. We hypothesized that one of the protective mechanisms may be the ability of the plasminogen system to enhance hepatocyte growth factor (HGF) effects, which have been reported to be anti-fibrotic in the lung. HGF is known to be sequestered in tissues by binding to extracellular matrix components. Following bleomycin administration, we found that HGF protein levels were higher in bronchoalveolar lavage fluid from PAI-1-/- mice compared to wild-type (PAI-1+/+) mice. This increase could be suppressed by administering tranexamic acid, which inhibits plasmin activity. Conversely, intratracheal instillation of urokinase into bleomycin-injured PAI-1+/+ mice to activate plasminogen caused a significant increase in HGF within bronchoalveolar lavage and caused less collagen accumulation in the lungs. Administration of an anti-HGF neutralizing antibody markedly increased collagen accumulation in the lungs of bleomycin-injured PAI-1-/- mice. These results support the hypothesis that increasing the availability of HGF, possibly by enhancing its release from extracellular matrix by a plasmin-dependent mechanism, is an important means by which activation of the plasminogen system can limit pulmonary fibrosis.

Indexed as

AnimalsAntimetabolites, AntineoplasticBleomycinBronchoalveolar Lavage FluidEnzyme InhibitorsFibrinolysinHepatocyte Growth FactorMicePlasminogen Activator Inhibitor 1Plasminogen ActivatorsPulmonary FibrosisReverse Transcriptase Polymerase Chain ReactionSignal TransductionTranexamic AcidUrokinase-Type Plasminogen ActivatorAntimetabolites, AntineoplasticBleomycinEnzyme InhibitorsFibrinolysinHepatocyte Growth FactorPlasminogen Activator Inhibitor 1Plasminogen ActivatorsTranexamic AcidUrokinase-Type Plasminogen Activator

Identifiers

PMID14982862
PMCPMC1614722
OpenAlexW2088668384

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.